Eli Lilly and Company (LLY)
After hours:
| Previous close | 755.91 |
| Open | 743.00 |
| Bid | 740.00 x 1200 |
| Ask | 740.00 x 900 |
| Day's range | 730.34 - 745.00 |
| 52-week range | 419.80 - 800.78 |
| Volume | |
| Avg. volume | 3,117,708 |
| Market cap | 698.519B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 108.72 |
| EPS (TTM) | 6.76 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | 5.20 (0.71%) |
| Ex-dividend date | 14 Feb 2024 |
| 1y target est | 855.36 |
Barrons.comAmazon Stock Is on a Roll. Here’s Why It’s on This Firm’s ‘Best Ideas List.’
Amazon reported strong first-quarter results, with revenue and operating income ahead of expectations. The company delivered operating income of $15.3 billion, above consensus of $11.3 billion, while reporting better-than-expected growth in both Amazon Web Services (+17.2% year over year versus Street +15%) and advertising (+24.3% Y/Y versus Street +23.5%). Amazon has now reported operating income above the high end of its guidance range for five consecutive quarters, and the company has a number of drivers for further margin expansion in place, including continued cost efficiencies within its fulfillment network as well as the ongoing mix shift toward higher-margin AWS and advertising revenue.
Yahoo FinanceAmgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
ZacksAmgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
